Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2Carcinoma, Transitional Cell 2Urologic Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 79Cisplatin 56pembrolizumab 32Paclitaxel 28Carboplatin 24Docetaxel 19Radiotherapy 17Mitomycin 16Doxorubicin 15atezolizumab 14BCG Vaccine 14Nivolumab 13Cystectomy 13Filgrastim 11vinflunine 10Methotrexate 10Vinblastine 9Fluorouracil 95-aminolevulinic acid hexyl ester 9Sunitinib 7Early Intervention, Educational 7durvalumab 6avelumab 6Taxes 6Methods 6Cystoscopy 6Albumin-Bound Paclitaxel 6enfortumab vedotin 5Trastuzumab 5Surveys and Questionnaires 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Urinary Bladder Neoplasms × apatorsen × Clear all
NCT01780545 2022-07-11

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

Hoosier Cancer Research Network

Phase 2 Completed
200 enrolled 11 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01454089 2016-10-07

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Achieve Life Sciences

Phase 2 Completed
183 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡